CAP death: What goes wrong when everything is right?

The Lancet Infectious Diseases

Volumn 15, Issue 9, 2015, Pages 995-996

  Wunderink, Richard G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DEATH; HUMAN; INTENSIVE CARE UNIT; MORTALITY; NOTE; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RESUSCITATION; RISK ASSESSMENT; SEPTIC SHOCK; UREA NITROGEN BLOOD LEVEL; FEMALE; MALE; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; PNEUMONIA, BACTERIAL;

EID: 84940467079     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00150-4     Document Type: Note

References (13)

1. Kochanek KD, Murphy SL, Xu J, Arias E Mortality in the United States, 2013. NCHS Data Brief 2014, 178:1-8.
2. The top 10 causes of death World Health Organization, (accessed June 23, 2015). http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
3. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
4. Kumar A, Haery C, Paladugu B, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006, 193:251-258.
5. Kojicic M, Li G, Hanson AC, et al. Risk factors for the development of acute lung injury in patients with infectious pneumonia. Crit Care 2012, 16:R46.
6. Iscimen R, Cartin-Ceba R, Yilmaz M, et al. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 2008, 36:1518-1522.
7. Plataki M, Kashani K, Cabello-Garza J, et al. Predictors of acute kidney injury in septic shock patients: an observational cohort study. Clin J Am Soc Nephrol 2011, 6:1744-1751.
8. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis 2015, on behalf of the Central Japan Lung Study Group, published online July 3. http://dx.doi.org/10.1016/S1473-3099(15)00151-6.
9. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
11. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384.
12. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized controlled trial. JAMA 2015, 313:677-686.
13. Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011, 183:1561-1568.